Vascugen

About Vascugen

Vascugen is a biotechnology company specializing in induced pluripotent stem cell (iPSC) therapy to develop and manufacture engineered vascular cells. The company's core technology focuses on creating vasculogenic cells capable of forming new blood vessels in oxygen-deprived tissues, which is particularly beneficial for diabetic patients at high risk of limb amputation. Vascugen operates in the regenerative medicine market, targeting healthcare providers and medical research institutions as its primary clients. The business model revolves around developing proprietary cell therapies and licensing its technology to medical institutions and pharmaceutical companies. Revenue is generated through licensing fees, research grants, and potential future sales of its cell therapy products.